Case Control Study
Copyright ©The Author(s) 2020.
World J Gastroenterol. Aug 21, 2020; 26(31): 4607-4623
Published online Aug 21, 2020. doi: 10.3748/wjg.v26.i31.4607
Figure 4
Figure 4 The relative abundance of proline and hydroxypurine in hepatocellular carcinoma patients, cirrhosis patients and healthy controls. A: Proline; B: Hydroxypurine. P < 0.05 in Kruskal-Wallis test in all three comparisons (C vs N, Y vs N, and C vs Y) of each metabolite.